Regulus Therapeutics Inc.: management transactions · United States · SEC (Form 4)

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc. (ticker: RGLS) is a U.S.-listed biopharmaceutical company traded on the Nasdaq market in the United States and focused on microRNA-based medicines. The company develops oligonucleotide therapeutics designed to inhibit dysregulated microRNA targets, with an initial emphasis on genetically defined orphan diseases, especially inherited kidney disorders. Its principal executive offices are in San Diego, California. ([regulusrx.com](https://www.regulusrx.com/about/?utm_source=openai)) Regulus was originally established in 2007, following work tied to Alnylam and Ionis around microRNA-targeting therapeutics, and it was converted into a Delaware corporation in January 2009. That history matters because it explains the company’s long-standing positioning as a science-driven, platform-oriented biotech rather than a broad commercial pharmaceutical business. Over time, Regulus has built expertise in RNA drug discovery and development, with a focus on mechanisms that regulate gene expression at the microRNA level. ([sec.gov](https://www.sec.gov/Archives/edgar/data/874015/000087401518000047/form10k.htm?utm_source=openai)) Operationally, Regulus is best described as a clinical-stage specialty biotech with a narrow but potentially differentiated pipeline. Its lead focus is ADPKD, or autosomal dominant polycystic kidney disease, where it is pursuing an anti-miR-17 strategy intended to address the underlying biology of the disease. The company’s lead asset, farabursen (RGLS8429), is the flagship program and the central driver of its value proposition. Regulus also highlights the strength of its intellectual-property position, including exclusive licensed IP from Alnylam and Ionis plus internal discoveries since inception. ([regulusrx.com](https://www.regulusrx.com/about/?utm_source=openai)) In competitive terms, Regulus occupies a niche within RNA therapeutics and genetic kidney disease. It is not a large diversified biotech; instead, it competes on scientific novelty, translational relevance, and clinical data quality. That makes the company highly dependent on clinical execution, regulatory outcomes, and capital discipline, but also gives it the potential for significant re-rating if its lead program demonstrates compelling efficacy and safety. ([regulusrx.com](https://www.regulusrx.com/about/?utm_source=openai)) A major recent development was the April 30, 2025 announcement that Regulus entered into a merger agreement with Novartis AG. Under the deal, Novartis agreed to acquire Regulus for $7.00 per share in cash at closing, with an additional contingent value right tied to a regulatory milestone for farabursen. For investors, this is the key headline: RGLS is no longer just a standalone microRNA story, but also a live M&A situation with a strategic buyer validating the platform and lead asset. ([nasdaq.com](https://www.nasdaq.com/press-release/regulus-therapeutics-enters-agreement-be-acquired-novartis-ag-2025-04-30?utm_source=openai))